Clinical TrialJul 9, 2026, 08:42 AM
MetaVia Completes Dose Titration in Phase 1 Obesity Trial for DA-1726
AI Summary
MetaVia Inc. announced the successful completion of dose titration for all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity. Patients are now receiving their highest target doses of 48 mg and 64 mg. The company reiterated that topline data from the trial is expected to be released in the fourth quarter of 2026, marking a significant milestone for the DA-1726 development program.
Key Highlights
- All enrolled active patients in Part 3 of the Phase 1 clinical trial for DA-1726 have completed dose titration.
- Patients are now receiving their highest target doses of 48 mg and 64 mg in both study cohorts.
- Topline data from the Phase 1 Trial is on track to be released in the fourth quarter of 2026.
- DA-1726 is a novel oxyntomodulin (OXM) analog targeting both GLP-1 and glucagon receptors for obesity.
- Previous Phase 1 MAD study showed 9.1% mean weight loss at 48 mg in 8 weeks.
Price Impact
More from MTVA